BridgeBio Pharma IncBBIO
Buy moreBuy more on a dip to our buy price, which is under today's $79.
- 7 good· Earnings beat
- 1 to watch· Funds trimming
$78.57−0.97 (−1.23%)
Price at 3:02 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNASDAQ · Healthcare · Large company
The price we'd buy BBIO at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Oct 29
- Yahoo Finance daily closes to Nov 9
Any one could move it to Keep
Next report
below84%
sales growth
Compared with the S&P 500
9 points
worse in one day
20 points
worse in five trading days
+25.1% in a yearsince Nov 10, 2025
The news behind our call
written Oct 30, 10:37 AM ETOct 30, 10:37 AM ET · 13 articles · 7 sources
BridgeBio holds $1.5 billion in cash and securities.
Attruby sales are rising alongside a Bayer milestone.
Healthcare breadth is expanding broadly.
What changed
From Yahoo Finance, BridgeBio Pharma Inc via Seeking Alpha, BridgeBio Pharma Inc via Yahoo Finance and 1 more
Overview
In plain numbers
- Revenue grew 167% from a year earlier, to $945.5M in the last twelve months.
- It loses 37 cents on every revenue dollar at the operating line, up from a loss of $8.22 in FY 2021.
- It burned $369.8M of free cash in the last twelve months.
- It owes $3.4B and holds $1.5B in cash and investments, so net debt is $1.8B.
Key figures
- Revenue (TTM)
- $946M
- Revenue growth, 1 year
- +167.3%
- Net income
- −$592M
- EPS (diluted)
- −$3.04
- Gross margin
- 94.3%
- Operating margin
- -37.3%
- Return on capital
- -17.7%
- Current ratio
- 2.09
- Buyback yield
- -2.39%
Key facts
- Company value
- $14.5B
- Today's range
- 78.4980.82
- Past year's range
- 63.3090.17
- Yesterday's close
- $79.54
- Swings vs the market
- 1.0×about the same